IBIO
iBio, Inc.
There isn't enough reported data to score IBIO yet.
IBIO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
IBIO's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
IBIO PE Valuation
IBIO has no meaningful PE right now: it lost money over the past year.
IBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IBIO's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
IBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.26 | +$1.14 |
| Q2 2026 | -$0.32 | +$1.43 |
| Q1 2026 | -$0.58 | +$1.84 |
| Q4 2025 | -$1.01 | +$1.77 |
| Q3 2025 | -$1.40 | +$5.32 |
| Q2 2025 | -$1.75 | +$9.31 |
IBIO lost $0.26 per share over the past year, a smaller loss than the year before.
IBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | +975% |
| Q2 2025 | $200K | +14% |
| Q2 2022 | $61K | -88% |
| Q1 2022 | $1.9M | +154% |
| Q4 2021 | $168K | -76% |
| Q3 2021 | $211K | -49% |
| Q2 2021 | $491K | -56% |
| Q1 2021 | $765K | +697% |
IBIO's revenue is recovering but still below its 2022 peak: $1M last quarter, up 975% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -776% | +5175 points |
| Q3 2025 | -5951% | N/A |
| Q2 2025 | -2599% | -651 points |
| Q4 2024 | -2210% | N/A |
| Q2 2024 | -1948% | N/A |
| Q3 2023 | -10206% | N/A |
| Q2 2022 | -27698% | -25776 points |
| Q1 2022 | -627% | +315 points |
IBIO's operating margin was −776% last quarter, up 1172 points from the same quarter a year ago.
IBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.5M | -$3.8M |
| Q2 2026 | -$6.2M | -$1.6M |
| Q1 2026 | -$6.1M | -$3M |
| Q3 2025 | -$5.7M | -$2M |
| Q2 2023 | -$5.5M | +$9.5M |
| Q1 2023 | -$3.7M | +$2.9M |
| Q4 2022 | -$10.6M | +$2.2M |
| Q3 2022 | -$16.4M | -$6M |
IBIO has burned cash in almost every quarter: −$28M over the past year, against −$17M the year before.
IBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +27% | +32M shares |
| 1 year | +1437% | +142M shares |
| 3 years | +34185% | +151M shares |
IBIO has 152M diluted shares, up 1437% from a year ago.
IBIO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | -0.0x | Net Cash |
IBIO has more cash than debt.
IBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.3 | Neutral |
| Stochastic | 8.3 | Oversold |
IBIO's weekly RSI is 30 (neutral) and its Stochastic is 8 (oversold).
IBIO PE vs Healthcare Sector
IBIO has no meaningful PE right now: it lost money over the past year.
IBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.87 | 13% below |
| 20 week MA | $1.19 | 36% below |
| 50 week MA | $1.68 | 55% below |
| 100 week MA | $1.73 | 56% below |
| 200 week MA | $4.93 | 85% below |
IBIO is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
IBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $115.0 | $580.0 | +404% |
| 2021 | $580.0 | $335.0 | -42% |
| 2022 | $335.0 | $8.60 | -97% |
| 2023 | $8.60 | $1.37 | -84% |
| 2024 | $1.37 | $2.45 | +79% |
| 2025 | $2.45 | $1.89 | -23% |
| 2026 YTD | $1.89 | $0.76 | -60% |
IBIO's yearly returns have swung widely, from +404% in 2020 to −97% in 2022. It's down 60% so far in 2026.